Sign in
4

Changes in Ownership

Summit Therapeutics Inc. Filed Acc 0001599298-22-000007

Options or other derivatives

  • Director acquired 72,872 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Mahatme Ujwala · Director

Table II: Derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2022-01-03 Grant or award : show line 1 in the form Stock Option (right to buy) +25,000 25,000 D
2022-01-03 Grant or award : show line 2 in the form Stock Option (right to buy) +47,872 $1.13 $54,095 72,872 D
Loading xslF345X03/wf-form4_164141670774490.xml…